Impacts of the removal of race-correction in lung pulmonary function tests on lung surgery

Race-correction for spirometry, a type of pulmonary function test, is commonly done in medical institutions across the United States.

Recently, the American Thoracic Society released recommendations to remove race-correction from spirometry tests, which could change the way surgeons think about selecting surgical candidates.

Spirometry tests are a noninvasive test that assesses the function of the lungs when being evaluated for a chest or lung disease, including lung cancers.

Within the United States, these exams offer adjustments for age, sex, and height as well as race-correction values for some racial and ethnic groups.

Currently, the use of race-correction for African Americans assumes a 10-15% deficiency in lung function compared to White Americans.

To date, the concern with race-correction in spirometry tests for African American patients has primarily centered on misdiagnosis and underdiagnosis of medical diagnoses such as asthma or chronic obstructive pulmonary disease.

However, limited research has focused on African Americans requiring surgery for lung cancer.

A recent study led by Sidra Bonner, M.D., M.P.H, M.S. a surgery resident at the University of Michigan Health, has now provided new information about the clinical impact of race-correction in pulmonary function tests for African American patients with lung cancer undergoing surgical evaluation.

In this study, most African American patients undergoing surgery currently had race-corrected values in spirometry testing before surgery.

Additionally, the study found that the removal of race-correction caused a significant reduction in the estimation of lung function from the test.

The study presented cardiothoracic surgeons with hypothetical cases of African American patients, with and without race-corrected spirometry results.

Research results found that the surgeons’ treatment recommendations significantly varied between the two hypothetical cases.

“The removal of race correction for African American patients has the potential to change who surgeons consider to be candidates for surgical intervention and what type of surgery may be performed,” said Bonner.

“It is important that race-correction in spirometry tests is removed given that it is based on the flawed concept of race as a biological factor. However, it is important to realize the implications of race-correction in spirometry tests differs between medical and surgical conditions. For African Americans with lung cancer being evaluated for surgery, this may exacerbate existing disparities in lung cancer care.”

Considering the coming changes, Bonner encourages surgeons to do research about how the change of removing race-correction may impact their practice.

“The change in pulmonary function test numbers could lead surgeons to believe that patients are at a higher risk for post-operative complications or mortality than they actually are,” said Bonner.

“Therefore, there is a need for surgeons to educate themselves about anticipated changes to spirometry testing in their own clinical practices and a wider need for surgical societies to provide new recommendations about surgical candidacy for lung cancer surgical resection in the light of the end of race-correction in spirometry.”

Study authors include Sidra Bonner, M.D., M.P.H., M.S., from the Department of Surgery, Center for Health Outcomes and Policy, and National Clinician Scholars Program at the University of Michigan, Ann Arbor, MI, Kiran Lagisetty, M.D., from the Section of Thoracic Surgery, Department of Surgery, University of Michigan, Ann Arbor, MI and the VA Ann Arbor Healthcare System, Department of Veterans Affairs, Ann Arbor, MI. Rishindra M. Reddy, M.D., M.B.A, from the VA Ann Arbor Heathcare System, Department of Veterans Affairs, Ann Arbor, MI, and the Michigan Society of Thoracic and Cardiovascular Surgeons General Thoracic Quality Collaborative, Ann Arbor, MI. Yadonay Engeda, B.A., from the University of Michigan Medical School, Ann Arbor, MI. Jennifer J. Griggs, M.D., M.P.H, from the Department of Internal Medicine, Division of Hematology and Oncology, Department of Health Management and Policy, School of Public Health University of Michigan, Ann Arbor, MI and the Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI. Thomas S. Valley, M.D., M.S.c, from the VA Ann Arbor Healthcare System, Department of Veterans Affairs, Ann Arbor, MI, the Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, the Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, and the Center for Bioethics and Social Sciences in Medicine, University of Michigan, Ann Arbor, MI.

Funding provided by the NIH T32 Institutional Multidisciplinary Research Training Program in Lung Diseases.